Pet Flavors names Loïc Le Hir de Fallois interim CEO: full analysis
Pet Flavors has appointed Dr. Loïc Le Hir de Fallois, PhD, as interim chief executive officer, effective May 6, 2026, putting a veteran animal health R&D executive at the helm of a company that sits upstream of many companion animal medications and supplements. The Melbourne, Florida-based company develops pharmaceutical-grade flavor bases and palatants used to improve acceptance of products for dogs, cats, and horses. (petfoodindustry.com)
The move fits into a broader transition already underway at Pet Flavors. In late 2021, Bessemer Investors made a majority investment in the company, describing the deal as its entry into the companion animal health market. At the time, Pet Flavors highlighted its role as a manufacturer of pharmaceutical-grade flavor bases and palatants made at a USDA-certified facility in Melbourne, with products used by major animal health drug producers. Since then, the company has continued to reposition itself, and in a recent corporate update said it had been adding capabilities following that investment and the retirement of its founder in summer 2024. (petfoodprocessing.net)
Pet Flavors said Le Hir de Fallois is a chemist with a background in small-molecule Chemistry, Manufacturing and Controls, or CMC. According to the company’s announcement as reported by industry media, he previously held senior leadership roles at Merial and Boehringer Ingelheim, most recently serving as executive director of pharmaceutical development U.S., where he led an R&D site and supported the development and launch of animal health products. Additional public records and conference materials tie him to Boehringer Ingelheim Animal Health and parasiticide-related development work, reinforcing the company’s framing of him as a technically deep operator rather than a purely commercial executive. (petfoodindustry.com)
The company’s recent governance changes provide more context. Pet Flavors announced that Randolph Legg, former president and head of commercial business at Boehringer Ingelheim Animal Health USA, joined the board, alongside Fabian Kausche, whom it described as a longtime R&D executive and leader at Boehringer Ingelheim, Merial, Novartis Animal Health, and Pfizer. In the interim CEO announcement, both board members endorsed Le Hir de Fallois, with Kausche pointing to his product development and team leadership background, and Legg emphasizing his experience supporting pharmaceutical scale-up and operations. That combination suggests the board is intentionally pairing commercial and technical animal health leadership as the company enters its next phase. (petflavors.com)
Industry reaction so far has been limited to the company’s own announcement and trade coverage, but the tone is consistent: Pet Flavors is leaning into science-led growth. Le Hir de Fallois said he sees an opportunity to expand the company’s impact in pet palatability and companion animal health. That matters because palatability is often treated as a formulation detail, yet for veterinary products it can directly affect whether pet parents can successfully administer a medication or supplement over time. (petfoodindustry.com)
Why it matters: For veterinary professionals, Pet Flavors’ leadership choice is notable because it points to continued investment in the less visible parts of product performance, especially formulation acceptability and manufacturing execution. Clinics may never interact with the company directly, but suppliers like Pet Flavors influence the usability of oral medications, supplements, and other companion animal products prescribed or recommended in practice. A leader with deep pharmaceutical development experience could help the company strengthen ties with drug makers and nutraceutical partners, potentially shaping the next generation of more acceptable, easier-to-administer products for pet parents. That’s particularly relevant as adherence remains a practical issue in long-term treatment and prevention. (petflavors.com)
The appointment also reflects a wider pattern in animal health, where specialized suppliers are increasingly being run by executives with big-pharma and R&D backgrounds. Pet Flavors has described itself as the only company solely focused on flavors for pharmaceutical and nutritional formulations for dogs, cats, and horses. If that positioning holds, the company’s strategic direction could have outsized influence in a narrow but important corner of the veterinary supply chain. (petflavors.com)
What to watch: The next signals will be whether Pet Flavors announces a permanent CEO search outcome, new customer or development partnerships, or expanded manufacturing and formulation capabilities. Given the company’s recent board additions, prior private equity backing, and emphasis on palatability science, the most likely near-term story is not a dramatic strategic pivot, but a more structured push to scale its role with animal health manufacturers in 2026. This is an inference based on the company’s recent leadership moves and stated priorities. (petflavors.com)